Dyadic InternationalDYAI
DYAI
About: Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Employees: 6
0
Funds holding %
of 7,331 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
28,900% more call options, than puts
Call options by funds: $290K | Put options by funds: $1K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0.49% less ownership
Funds ownership: 17.29% [Q4 2024] → 16.81% (-0.49%) [Q1 2025]
17% less funds holding
Funds holding: 41 [Q4 2024] → 34 (-7) [Q1 2025]
18% less capital invested
Capital invested by funds: $8.33M [Q4 2024] → $6.83M (-$1.5M) [Q1 2025]
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for DYAI.
Financial journalist opinion
Based on 3 articles about DYAI published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share. The Company expects the gross proceeds from this offering to be approximately $5.75 million, before deducting the underwriting discount and other offering expenses. Closing of the offering is expected to occur on August 1, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
4 days ago
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock. Closing of the offering is expected to occur on August 1, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
5 days ago
Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it has commenced an underwritten public offering of shares of common stock.
Neutral
Business Wire
1 month ago
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
JUPITER, Fla.--(BUSINESS WIRE)---- $DYAI #BioSolutions--Dyadic International, Inc. announces strategic rebrand to Dyadic Applied BioSolutions to reflect focus on commercializing non-therapeutic proteins.
Neutral
GlobeNewsWire
2 months ago
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets.
Neutral
GlobeNewsWire
3 months ago
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025.
Neutral
GlobeNewsWire
3 months ago
Dyadic to Present at World Vaccine Congress | Washington
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C.
Neutral
Seeking Alpha
4 months ago
Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q4 2024 Earnings Conference Call March 26, 2025 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Operating Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Vernon Bernardino - HC Wainwright Dick Williams - Williams Resource Group Operator Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
4 months ago
Dyadic Reports 2024 Year-End Financial Results and Business Updates
JUPITER, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non- pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the full year 2024, highlighting significant progress in commercializing its proprietary Dapibus™ and C1 microbial protein production platforms and driving long-term growth opportunities.
Neutral
GlobeNewsWire
4 months ago
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025.
Charts implemented using Lightweight Charts™